Clinical Trials Browser

Solid Tumors × cemiplimab × 90 days × Clear all

NCT06651593 2026-05-06

Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors

Phase 2 Recruiting

Other solid neoplasm

Solid Tumors